person · Reporting owner

ROBERTS EIRY

Disclosed activity across 3 companies

Tapewire entity: 44455
SEC CIK: 0001727606

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bausch Health Companies Inc.BHC · Entity 4363	Director	May 22, 2026	May 26, 2026
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655	Chief Medical Officer	September 28, 2026	October 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bausch Health Companies Inc.

Report date May 22, 2026 · Filed May 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	45,871	Reported balance After 2026-05-22 transaction · row 1 1 source row Row 1 · 2026-05-22 · Grant · Acquired 45,871 · Balance 45,871 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.

NEUROCRINE BIOSCIENCES INC

Report date September 28, 2026 · Filed October 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	51,331	Reported balance Holding disclosure · report date 2026-09-28 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 51,331 F1: 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $102.90 · Expires 2030-02-06	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.63 · Expires 2031-02-08	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.02 · Expires 2032-01-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F4: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $103.52 · Expires 2033-02-13	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $133.84 · Expires 2034-02-13	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $136.69 · Expires 2034-12-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance Not disclosed F7: Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2035-02-12	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance Not disclosed F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $124.12 · Expires 2036-02-13	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · Balance Not disclosed F9: Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.
Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $103.52 · Expires 2033-02-13	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $133.84 · Expires 2034-02-13	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.18 · Expires 2035-02-12	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance Not disclosed F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F10: Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F12: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F13: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F14: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-28 · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · Balance Not disclosed F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F15: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.

Filing footnotes · ownership attribution and instrument terms

F1: 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

F2: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

F3: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

F4: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.

F5: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

F6: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

F7: Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.

F8: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

F9: Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

F10: Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.

F11: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F12: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.

F13: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.

F14: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.

F15: Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMICUS THERAPEUTICS, INC.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-27 transaction · row 1 1 source row Row 1 · 2026-04-27 · Disposition to issuer · Disposed 76,275 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10	Direct	Reported balance After 2026-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-27 · Disposition to issuer · Disposed 40,625 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09	Direct	Reported balance After 2026-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08	Direct	Reported balance After 2026-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06	Direct	Reported balance After 2026-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05	Direct	Reported balance After 2026-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).

F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

F3: Each Option was fully vested.

F4: Each Option vested in full in connection with consummation of the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 12, 2023 Filed Dec 14, 2023 22:22 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	6,978	$81.05	$565,566.90	Disclosure SEC source: 0001209191-23-058683 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 08, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	100	$81.05 Strike: $81.05	$8,105.00	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 18 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,365 Underlying: Common Stock · 100 shares Expires 2029-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Option granted February 7, 2019 and vested monthly over four years. Read SEC document
December 08, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	200	$81.05 Strike: $81.05	$16,210.00	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 17 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,465 Underlying: Common Stock · 200 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Option granted February 7, 2019 and vested monthly over four years. Read SEC document
December 08, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	100	$120.00	$12,000.00	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 12 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · balance_after: 28,366 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document
December 08, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	100	$81.05	$8,105.00	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 11 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 08, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	200	$120.16	$24,031.00	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 10 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 08, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	200	$81.05	$16,210.00	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 9 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	11,775	$81.05 Strike: $81.05	$954,363.75	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 16 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,665 Underlying: Common Stock · 11,775 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Option granted February 7, 2019 and vested monthly over four years. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	14,140	$79.02 Strike: $79.02	$1,117,342.80	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 15 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,005 Underlying: Common Stock · 14,140 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Option granted January 31, 2022 and vested monthly over four years. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	12,742	$77.81 Strike: $77.81	$991,455.02	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 14 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,742 shares Expires 2028-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	38,722	$77.81 Strike: $77.81	$3,012,958.82	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · derivative · entry 13 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,742 Underlying: Common Stock · 38,722 shares Expires 2028-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	11,775	$120.37	$1,417,374.41	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 8 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	11,775	$81.05	$954,363.75	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 7 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	14,140	$120.37	$1,702,053.01	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 6 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	14,140	$79.02	$1,117,342.80	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 5 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	12,742	$120.37	$1,533,773.65	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	12,742	$77.81	$991,455.02	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	38,722	$120.37	$4,661,118.16	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $121.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 07, 2023 Filed Dec 11, 2023 23:18 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	38,722	$77.81	$3,012,958.82	Disclosure SEC source: 0001209191-23-058116 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 06, 2023 Filed Dec 9, 2023 00:09 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	8,396	$77.81 Strike: $77.81	$653,292.76	Disclosure SEC source: 0001209191-23-057986 · doc4.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,464 Underlying: Common Stock · 8,396 shares Expires 2028-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted January 8, 2018 and vests at 25% upon first anniversary (January 8, 2019) and remaining 75% vesting in 36 equal monthly installments beginning February 8, 2019. Read SEC document
December 06, 2023 Filed Dec 9, 2023 00:09 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	8,396	$120.03	$1,007,780.28	Disclosure SEC source: 0001209191-23-057986 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: 28,336 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document
December 06, 2023 Filed Dec 9, 2023 00:09 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	8,396	$77.81	$653,292.76	Disclosure SEC source: 0001209191-23-057986 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 21, 2023 Filed Aug 24, 2023 00:20 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	3,198	$107.38	$343,387.81	Disclosure SEC source: 0001209191-23-047140 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,521 F1 · kind: Sale of 3,198 shares of common stock issued upon vesting of 6,075 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,877) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: 25,459 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:38 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	30,474	$0.00 Strike: $12.62	$0.00	Disclosure SEC source: 0001209191-23-036422 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,474 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:38 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	8,584	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036422 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,014 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
April 24, 2023 Filed Apr 27, 2023 01:22 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	14,400	$103.48	$1,490,058.72	Disclosure SEC source: 0001209191-23-025763 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,644 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted on February 23, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.84 to $104.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:15 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	8,453	$0.00	$0.00	Disclosure SEC source: 0001209191-23-009889 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,453 Underlying: Common Stock · 8,453 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:15 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantStock Option · Derivative	52,532	$0.00 Strike: $103.52	$0.00	Disclosure SEC source: 0001209191-23-009889 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,532 Underlying: Common Stock · 52,532 shares Expires 2033-02-13 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document
February 08, 2023 Filed Feb 9, 2023 00:40 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	980	$104.16	$102,072.00	Disclosure SEC source: 0001209191-23-007916 · doc4.xml · nonDerivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,015 F8 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F9 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.79 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:40 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	12,801	$102.41	$1,310,918.41	Disclosure SEC source: 0001209191-23-007916 · doc4.xml · nonDerivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,135 F5 · kind: Sale of 12,801 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,497) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $103.89 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:40 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,623	$102.35	$166,114.05	Disclosure SEC source: 0001209191-23-007916 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,638 F3 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.56 to $103.87 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 06, 2023 Filed Feb 9, 2023 00:40 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,121	$105.80	$118,602.25	Disclosure SEC source: 0001209191-23-007916 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,176 F1 · kind: Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.99 to $108.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
January 31, 2023 Filed Feb 2, 2023 22:28 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,457	$109.99	$160,253.54	Disclosure SEC source: 0001209191-23-006282 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,171 F1 · kind: Sale of 1,457 shares of common stock issued upon vesting of 2,768 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,311) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:11 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	45,423	$0.00 Strike: $8.55	$0.00	Disclosure SEC source: 0001209191-22-035847 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,423 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:11 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	12,671	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035847 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,430 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
February 08, 2022 Filed Feb 10, 2022 00:06 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	980	$79.52	$77,930.58	Disclosure SEC source: 0001209191-22-008216 · doc4.xml · nonDerivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,625 F5 · kind: Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.96 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:06 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,121	$80.80	$90,574.00	Disclosure SEC source: 0001209191-22-008216 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,746 F3 · kind: Sale of 1,121 shares of common stock issued upon vesting of 2,126 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,005) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.99 to $81.36 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:06 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,623	$80.77	$131,085.81	Disclosure SEC source: 0001209191-22-008216 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,741 F1 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.76 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
January 31, 2022 Filed Feb 3, 2022 00:52 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	11,074	$0.00	$0.00	Disclosure SEC source: 0001209191-22-006582 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,074 Underlying: Common Stock · 11,074 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. Read SEC document
January 31, 2022 Filed Feb 3, 2022 00:52 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantStock Option · Derivative	75,411	$0.00 Strike: $79.02	$0.00	Disclosure SEC source: 0001209191-22-006582 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,411 Underlying: Common Stock · 75,411 shares Expires 2032-01-31 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document
January 10, 2022 Filed Jan 12, 2022 22:53 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	2,632	$74.50	$196,087.68	Disclosure SEC source: 0001209191-22-003104 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,279 F1 · kind: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F1 · shares: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 10, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $72.14 to $76.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes an aggregate of 218 shares purchased on February 26, 2021 and August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document
June 10, 2021 Filed Jun 14, 2021 23:04 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	40,625	$0.00 Strike: $10.71	$0.00	Disclosure SEC source: 0001209191-21-040374 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Common Stock · 40,625 shares Expires 2031-06-10 F2 · derivative.exercise_date: These stock options vest and become exercisable over a period of four years, with 25% vesting on the first anniversary of the date of grant and the remainder vesting ratably each month thereafter. Read SEC document
June 10, 2021 Filed Jun 14, 2021 23:04 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	22,759	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040374 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,759 F1 · shares: These restricted stock units (RSUs) vest over a period of four years, with 25% vesting on the first anniversary of the grant date and 25% on each anniversary thereafter. Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	7,439	$0.00	$0.00	Disclosure SEC source: 0001209191-21-009123 · doc4.xml · derivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantStock Option · Derivative	44,632	$0.00 Strike: $117.63	$0.00	Disclosure SEC source: 0001209191-21-009123 · doc4.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,632 Underlying: Common Stock · 44,632 shares Expires 2031-02-08 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,623	$116.83	$189,607.30	Disclosure SEC source: 0001209191-21-009123 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,693 F3 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:21 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	740	$116.67	$86,336.61	Disclosure SEC source: 0001209191-21-009123 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,231 F1 · kind: Sale of 740 shares of common stock issued upon vesting of 2,126 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,386) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 08, 2021 Filed Mar 29, 2021 10:24 UTC Amendment	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantStock Option · Derivative	49,049	$0.00 Strike: $117.63	$0.00	Disclosure SEC source: 0001209191-21-023387 · doc4a.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:17 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	2,632	$111.06	$292,297.29	Disclosure SEC source: 0001209191-21-003239 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,845 F1 · kind: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.10 to $112.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
November 12, 2020 Filed Nov 16, 2020 23:23 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	2,257	$90.74	$204,809.89	Disclosure SEC source: 0001209191-20-058553 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,477 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.